Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Home Depot

Pembina Pipeline

3 Growth Stocks That Raised Their Guidance This Year

Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.

Thermo Fisher's (TMO) Autoimmune Disease Test Gets FDA Nod

Thermo Fisher's (TMO) new deal with TransMIT will advance the use of the AP-SMALDI5 AF ion source with Orbitrap MS technology for spatial multi-omics applications.

Thermo Fisher (TMO) to Promote Mass Spectrometry Imaging

QIAGEN

LONDON--(BUSINESS WIRE)--Relation Therapeutics Closes $25 Million Seed Financing and Names David Roblin as CEO and Lindsay Edwards as CTO

Relation Therapeutics, the Active-Graph Machine Learning Drug Discovery Company, Names David Roblin as CEO and Lindsay Edwards as CTO

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific's PPD clinical research business has been named Clinical Research Company of the Year for the third consecutive year.

Thermo Fisher Scientific's Clinical Research Business Named Clinical Research Company of the Year for Third Consecutive Year

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific is offering an IVDR version of the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System globally.

Thermo Fisher Scientific Updates Applied Biosystems QuantStudio 5 Dx Real-Time PCR System to Comply with IVDR Regulations

MINNEAPOLIS--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, is showcasing new instruments, workflows, software and industry collaborations that enable customers to generate new analytical insights and accelerate next generation vaccine and therapy development. The company will showcase these innovations during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022, in th

Thermo Fisher Scientific Showcases Solutions for Accelerating Next Generation Vaccine and Therapy Research and Unlocking Deeper Analytical Insights

SAN JOSE, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Recognizes Tandem Mass Tag Grant Awards to top proteomics researchers for outstanding innovation and societal impact.

Thermo Fisher Scientific Recognizes Tandem Mass Tag Grant Award Winners

MINNEAPOLIS--(BUSINESS WIRE)--Co-marketing agreement with TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues.

Thermo Fisher Scientific Collaborates with TransMIT GmbH on a High-Performance Orbitrap Mass Spectrometry Imaging Platform

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company's commitment to society and stakeholders providing detailed insight into the company's CSR progress and environmental, social and governance (ESG) efforts. “Our Mission to enable our customers to make the world healthier, cleaner and safer guides all of our actions,” said Marc N.

Thermo Fisher Scientific Releases Corporate Social Responsibility Report

Investors are optimistic about Thermo Fisher's (TMO) robust y/y revenue growth in the Analytical Instruments, and the Laboratory Products and Biopharma Services segments.

Here's Why You Should Retain Thermo Fisher (TMO) for Now

Thermo Fisher (TMO) witnesses core business strength across segments, end markets, and geographies.

Thermo Fisher (TMO) North America Sales Grow, Margin Woe Stays

AbbVie

Biohaven Pharmaceutical Hld

Here are 3 top health care stocks to watch in the stock market right now.

Best Health Care Stocks To Invest In 2022? 3 Names To Watch

Thermo Fisher's (TMO) collaboration with Qatar Genome Program will utilize the power of genomics to enhance the standard of healthcare for the Qatari population.

Thermo Fisher (TMO) to Advance Precision Medicine in Qatar

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been recognized for its successful enterprise learning and development programs.

Thermo Fisher Scientific's Clinical Research Business Receives ATD Award for Employee Talent Development

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific and Qatar Genome Program have partnered to accelerate genomic research and clinical applications of predictive genomics.

Thermo Fisher Scientific and Qatar Genome Program Partner to Advance Precision Medicine

WALTHAM, Mass.--(BUSINESS WIRE)--To support the Greater Boston biotech ecosystem, Thermo Fisher Scientific is joining forces with biotech incubator LabShares Newton to provide instruments, lab equipment and consumables to help early-stage life sciences companies accelerate their drug discovery efforts. LabShares provides fully furnished lab space, services and equipment to more than 25 biotech companies, alleviating logistics constraints to help them bring novel therapeutics to market. Thermo F

Thermo Fisher Scientific and LabShares Partner to Support Emerging Boston Biotechs

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been recognized for excellence in the 2022 CRO Leadership Awards.

Thermo Fisher Scientific's Clinical Research Business Honored in CRO Leadership Awards

The company is coming off a strong quarter and expects that pattern to continue.

This Growth Stock Is Raising Guidance Despite Multiple Headwinds

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been recognized for its leadership in digital and decentralized clinical trials

Thermo Fisher Scientific's Clinical Research Business Named a Leader in Decentralized Clinical Trial Solutions by ISG

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific launches QualTrak suite of qPCR biopharma offerings to help accelerate drug development .

Thermo Fisher Scientific Introduces QualTrak Biopharma qPCR Solutions to Streamline Biologics Development and Compliance

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 12:20 p.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in

Thermo Fisher Scientific to Present at BofA Securities 2022 Healthcare Conference

Thermo Fisher's (TMO) core business strength was broad-based across segments, end markets, and geographies.

Thermo Fisher (TMO) End Markets Strong, Margin Under Pressure

The company took on a big acquisition and still delivered strong, profitable numbers.

Thermo Fisher's Q1 Results Show Why It's a Safe Growth Stock to Own

Thermo Fisher Scientific Inc. (NYSE:TMO ) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Rafael Tejada – Vice President, Investor Relations Marc Casper – Chairman, President, and Chief Executive Officer Stephen Williamson – Senior Vice President and Chief Financial Officer Conference Call Participants Jack Meehan – Nephron Research Patrick Donnelly – Citi Derik De Bruin – Bank of America Tejas Savant – Morgan Stanley Vijay Kumar – Evercore Puneet Souda – SVB Leerink Securities Dan Arias – Stifel Matt Sykes – Goldman Sachs Operator Good morning, ladies and gentlemen, and welcome to Thermo Fisher Scientific 2022 First Quarter Conference Call. My name is Nadia, and I'll be coordinating your call today.

News for Thermo Fisher Scientific Stock (TMO)